Hereditary Cancer Panel denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why This Denial Happens

BCBS's medical necessity denial for hereditary cancer panel testing typically means the plan reviewed the submitted information and concluded the patient's personal history, family history, or clinical presentation did not meet the thresholds in its coverage policy. These denials often result from incomplete documentation at the time of initial authorization — missing family history detail, ambiguous diagnosis codes, or an absence of a clinician letter explaining the clinical reasoning — rather than a genuine absence of medical need. Correcting the record at the internal appeal stage resolves a large proportion of these cases.

## Why This Is Appealable

Medical necessity determinations must be based on the clinical facts in the record. If the initial submission was incomplete, the appeal is an opportunity to supply the missing documentation. BCBS's reviewer at the internal appeal level is required to conduct a fresh, full review of all newly submitted evidence. If BCBS upholds the denial, an independent external reviewer under ACA §2719 will evaluate the complete record against objective clinical standards — and is not bound by BCBS's internal policy alone.

## Federal Appeal Framework

• Internal appeal: Submit within the deadline stated on the denial notice (often 180 days). BCBS must issue a decision within 30 days (standard pre-service) or 60 days (post-service).
• External review (ACA §2719): After final internal denial, you have the right to independent external review — generally within four months of the final adverse determination.
• Expedited review: Request this if the patient's condition is urgent and a standard timeline would jeopardize health or treatment planning.
• ERISA §503: Self-funded plan members retain full-and-fair review rights and federal court access after exhaustion.

## Documentation to Gather

1. Detailed family history pedigree — a structured document from the ordering clinician listing first- and second-degree relatives' cancer diagnoses, ages at diagnosis, and bilateral status where applicable. 2. Personal diagnosis records — pathology reports, operative notes, or clinical notes confirming current or prior cancer diagnosis and histologic type. 3. Ordering clinician's medical necessity letter — explicitly stating the clinical question the panel is intended to answer, how results will alter medical management, and why testing is indicated now. 4. Applicable guideline organization's testing criteria — reference the organization by name (e.g., NCCN) and submit the guideline document; the clinician's letter should state the patient meets the criteria described therein. 5. BCBS published medical policy for hereditary cancer genetic testing — to ensure the appeal addresses every criterion the plan uses.

## Criteria-Mapping Structure

Obtain the current BCBS medical policy and list each medical necessity criterion as a separate row in a two-column table. In the right column, provide the specific clinical fact — drawn from chart notes, pathology, and the clinician letter — that satisfies that criterion. Do not leave any criterion unanswered; a gap in the mapping is the most common reason a well-documented appeal is still denied. Attach all supporting records as labeled exhibits referenced in the table.